Please assess the completion status of the following clinical trial:

Trial Title: Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent and aged between 18 and 75 years of age.~* Meets DSM-IV criteria for a primary diagnosis of schizophrenia.~* Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.~* Able and agrees to remain off prior antipsychotic medication for the duration of study.~* Good physical health on the basis of medical history, physical examination, and laboratory screening.~* Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.~Exclusion Criteria:~* Considered by the investigator to be at imminent risk of suicide or injury to self, others or property.~* Any chronic organic disease of the CNS (other than schizophrenia).~* Used investigational compound within 30 days.~* Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lurasdione 40mg tablets (Type: EXPERIMENTAL): None
- 120mg (Type: EXPERIMENTAL): None
- 15mg Olz (Type: ACTIVE_COMPARATOR): None
- Sugar pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).